Bianco A, Marcatili P, D'Auria D, Sorrentino P, Zofra S
Istituto di Tisiologia e Malattie dell'Apparato Respiratorio S. Marcatili, Facoltà di Medicina e Chirurgia, Seconda Università degli Studi di Napoli.
Ann Ital Med Int. 1996 Apr-Jun;11(2):114-8.
Over the past years, a number of serum components have been confirmed as useful biological markers of lung cancer. Although none have been sensitive or specific enough to enable early diagnosis, they do seem to facilitate the monitoring and prediction of disease prognosis. We studied tumor markers in 66 patients with lung cancer: serum levels of ferritin, carcinoembryonic antigen (CEA), alpha-fetoprotein (alpha-FP); tissue polypeptide antigen (TPA), cytocheratin fragment 19, 21-1 (CYFRA 21-1) and carbohydrate antigen 125 (CA 125) levels were measured and correlated to tumor stage and histological type. Postulating a specificity of 95% versus benign diseases of the lung, we confirmed the following diagnostic sensitivity for the markers: ferritin = 39.3%; CEA = 42.4%; alpha-FP = 5.1%; TPA = 57.5%; CYFRA 21-1 = 65.1%; CA 125 = 46.9%. CYFRA 21-1 showed significantly higher sensitivity in non small cell lung cancer patients than in those with small cell lung cancer (Wilcoxon, p = 0.02). Moreover since survival time was significantly shorter in patients with high serum CYFRA 21-1, these levels seemed to be correlated with the prognosis.
在过去几年中,多种血清成分已被确认为肺癌有用的生物标志物。尽管没有一种标志物足够敏感或特异到能够实现早期诊断,但它们似乎确实有助于监测和预测疾病预后。我们研究了66例肺癌患者的肿瘤标志物:检测了铁蛋白、癌胚抗原(CEA)、甲胎蛋白(α-FP)、组织多肽抗原(TPA)、细胞角蛋白片段19、21-1(CYFRA 21-1)和糖类抗原125(CA 125)的血清水平,并将其与肿瘤分期和组织学类型相关联。假设与肺部良性疾病相比特异性为95%,我们确定了以下标志物的诊断敏感性:铁蛋白=39.3%;CEA=42.4%;α-FP=5.1%;TPA=57.5%;CYFRA 21-1=65.1%;CA 125=46.9%。CYFRA 21-1在非小细胞肺癌患者中的敏感性显著高于小细胞肺癌患者(Wilcoxon检验,p=0.02)。此外,由于血清CYFRA 21-1水平高的患者生存时间明显较短,这些水平似乎与预后相关。